Pulmonology

New ASCENT-COPD data show the therapy's benefit in reducing cardiovascular events among high-risk patients, along with significant exacerbation reduction.

The fixed-dose therapy was shown to reduce exacerbations, regardless of patient history, among those with increased cardiovascular risk.

What the introduction of aclidinium/formoterol could mean for patients with COPD.

The approved label update now indicates the therapy delays disease progression when used in combination with an approved oral background PAH therapy.

A new assessment from CHRONICLE study data show patient-reported assessment on disease control may be more accurate.

The drug class has become a mainstay in clinical practice and treatment plans. But could it reach greater, and wider, indications?

Investigators found similar rescue treatment use among patients who do and do not have frequent exacerbations.

A study observing the effect of formulary changes to children with asthma show FEV and FEF scores worsened significantly when switching inhaler types.

The most recent CDC data, presented at CHEST 2019, show nearly 1500 patients have reported an associated lung injury, and 33 have died.

A new study shows adult e-cigarette use in the US was steadily dropping since 2014— before spiking in 2018 among adults aged 18-24 years.

The geko device is designed to increase blood circulation and edema reduction to prevent venous thrombosis in non-surgical patients.

The United States Food and Drug Administration has accepted a BLA for Viaskin Peanut from DBV Technologies for the treatment of peanut-allergic children ages 4 to 11, which previously withdrew a BLA in 2018 after request from the FDA requested additional data on its manufacturing procedures and quality controls.

The indication makes it the first respiratory biologic available either at home or in a professional setting, with eight-week maintenance dosing.

Trelegy Ellipta could become the first triple-combination, single-inhaler therapy approved for the treatment of both asthma and COPD.

An expert with the American Lung Association will lead discussion on one of the greatest drivers of death in the US.

The investigative ICS/LAMA/LABA inhaler therapy reported positive findings from its phase 3 ETHOS trial in August, though the results were not included in the FDA application.

The 12-year update highlights promising novel therapy classes, and sets disparities between pediatric and adult chronic cough treatment.

From immunotherapy to biologics, the field of allergy pharmacotherapy is looking promising.

Results from the TRIMARAN and TRIGGER trials show significant benefits for 2 different doses of the ICS/LABA/LAMA combination.

How can physicians and specialists navigate testing options and potential risk factors to ensure patients are diagnosed and treated expediently and accurately?

A new study from ERS showed the technological material common among training athletes could help physicians monitor patients with COPD.

There has been significant changes in understanding surrounding food allergy testing. What do parents need to know?

A new study from the ERS International Congress shows a trio of air pollutants are associated with significant increases in all-cause infant mortality in the UK.

A comparative assessment of step-up therapy strategies for black patients with inadequately controlled asthma showed varying responses.

After receiving FDA approval for add-on adult severe chronic rhinosinusitis with nasal polyps treatment this June, the biologic has reported significant improvement in 24- and 52-week outcomes.